$NAMS

NewAmsterdam Pharma Co N.V. (NAMS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease - SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeabl

NewAmsterdam Pharma (NAMS) received European Commission approval for its cholesterol drug obicetrapib, marking its first global regulatory approval. The stock has seen a recent bounce, up 3.28% to $23.32, following a period of decline. Analysts suggest the company may be undervalued with an implied fair value of $50.92, but risks include potential trial failures and equity dilution.

NewAmsterdam Pharma Co N.V. (NAMS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 21, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) along with its partner Menarini Group (“Menarini”) announced that the European Commission (“EC”) has granted marketing authorization for Ubeslo ® (obicetrapib 10 mg monotherapy) and Ev

NewAmsterdam Pharma (NAMS) and Menarini Group received European Commission approval for Ubeslo and Evlarco, treatments for high LDL-C. Data shows up to 50% LDL-C reduction. NAMS may receive royalties and milestone payments. NAMS stock is up 1.53% at $22.92.

NewAmsterdam Pharma (NAMS) shares rose 4% after CEO Michael H. Davidson bought 10,000 shares at $22.65 each, totaling $226.5K. Davidson now holds 792,923 shares directly and 285,715 indirectly. The purchase was disclosed in an SEC Form 4 filing. Investing.com's AI tool, ProPicks AI, evaluates NAMS among other companies using financial metrics.

Davidson Michael H. (Chief Executive Officer) purchased 10,000 shares of NewAmsterdam Pharma Co N.V. (NAMS) at $22.65 ($0.23M total) on 2026-09-14.

Novartis (NVS) and Ionis (IONS) reported that their drug pelacarsen failed to reduce cardiovascular risks, despite lowering Lp(a) levels. This led to declines in NewAmsterdam Pharma (NAMS), Amgen (AMGN), and Eli Lilly (LLY) stocks. The news impacted biotech stocks on Tuesday.

Kastelein Johannes Jacob Pieter (Chief Scientific Officer) sold 125,000 indirectly-held shares of NewAmsterdam Pharma Co N.V. (NAMS) at $26.91 ($3.36M total) on 2026-08-24 under a Rule 10b5-1 trading plan.

NewAmsterdam Pharma Co N.V. (NAMS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 10, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) appointed Robert W. Gunning, age 55, as its principal

NewAmsterdam Pharma Co N.V. (NAMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results – Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe – – PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q20